Travere Therapeutics, Inc. (TVTX) — DEF 14A Filings
All DEF 14A filings from Travere Therapeutics, Inc.. Browse 2 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (2)
-
Travere Therapeutics 2024 Executive Compensation Details
— Apr 1, 2025 Risk: medium
Travere Therapeutics, Inc. filed its DEF 14A on April 1, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation, includin -
Travere Therapeutics Announces 2024 Annual Meeting of Stockholders on May 8, 2024
— Mar 27, 2024 Risk: low
Travere Therapeutics, Inc. (TVTX) filed a Proxy Statement (DEF 14A) with the SEC on March 27, 2024. Travere Therapeutics, Inc. will hold its 2024 Annual Meeting
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX